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ABSTRACT 		
Keratin 76 (Krt76) is expressed in the differentiated epithelial layers of skin, oral cavity and 
squamous stomach. Krt76 downregulation in human oral squamous cell carcinomas (OSCC) 
correlates with poor prognosis. We show that genetic ablation of Krt76 in mice leads to spleen 
and lymph node enlargement, an increase in regulatory T cells (Tregs) and high levels of pro-
inflammatory cytokines. Krt76-/- Tregs have increased suppressive ability correlated with 
increased CD39 and CD73 expression, while their effector T cells are less proliferative than 
controls. Loss of Krt76 increases carcinogen-induced tumours in tongue and squamous stomach. 
Carcinogenesis is further increased when Treg levels are elevated experimentally. The 
carcinogenesis response includes upregulation of pro-inflammatory cytokines and enhanced 
accumulation of Tregs in the tumour microenvironment. Tregs also accumulate in human OSCC 
exhibiting Krt76 loss. Our study highlights the role of epithelial cells in modulating 
carcinogenesis via communication with cells of the immune system. 
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INTRODUCTION 
 
Keratins, the intermediate filament proteins of epithelial cells, are essential for normal tissue 
function, acting as a scaffold that enables cells to resist stress and damage1. Mutations that impair 
keratin assembly have been identified in a range of human skin disorders, typically leading to skin 
blistering or abnormal differentiation2. Recent studies have highlighted a novel role for keratins 
as regulators of inflammation and immunity in epithelia 3-8. 
 
Krt76 is a type II intermediate filament protein expressed in the differentiating, non-proliferative 
layers of a subset of stratified epithelia in human and mouse 9. Krt76 is the most significantly 
downregulated gene encoding a structural protein in human oral squamous cell carcinoma 
(OSCC) and correlates strongly with poor prognosis10. OSCC arises from the multilayered 
epithelial lining of the mouth and the lips. It involves mostly the tongue, but can also occur in the 
floor of the mouth, gingiva, lip, cheek and palate. Despite advances in treatment, the 5 year 
survival rate for OSCC remains stubbornly low, at 50-60% 11. 
 
In patients, KRT76 is detected in 100% of normal gingivobuccal epithelial biopsies, 44% of oral 
preneoplastic lesions and 35% of OSCC10. However, Krt76-null mice do not develop 
spontaneous OSCC, indicating that loss of Krt76 alone is not sufficient to induce tumours10. 
Nonetheless, genetic ablation of Krt76 in mice results in skin barrier defects, epidermal 
hyperproliferation and inflammation12,13, with mild hyperplasia and keratinization of the buccal 
epithelium 10.  
 
Here we have investigated the role of Krt76 in oral and stomach epithelial homeostasis and the 
response of those tissues to the chemical carcinogen 4-nitroquinoline N-oxide (4NQO) 14, which 
mimics the carcinogenic effects of tobacco and alcohol ingestion15. We provide evidence for a 
previously unidentified role of Krt76 in regulating immunity in mice and demonstrate its 
importance in tumour progression. 
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RESULTS 
 
Keratin 76 is expressed in oral epithelia and stomach 
To analyse Krt76 expression and function, we used Krt76 mutant mice (Krt76tm1a(KOMP)Wtsi) 
generated by the Wellcome Trust Sanger Institute (WTSI) Mouse Genetics Project 13,16,17 (Figure 
1a). As a result of splicing of the lacZ trapping element to Krt76 exon 2, homozygous mice do 
not express Krt76 (Krt76-/-). Heterozygous mice (Krt76+/-), expressing one copy of Krt76 and 
one copy of the lacZ reporter under the control of the endogenous promoter, were used to 
visualize Krt76 expression in the oral cavity and stomach. Krt76 was first expressed at embryonic 
day 17.5 (E17.5) in the tongue, palate and stomach (Figure 1b-c) and expression continued in 
those locations throughout adulthood (Figure 1e-i). Expression in the tongue occurred 
predominantly on the dorsal surface and lateral border, with fewer cells labelled in the ventral 
tongue (Figure 1c-e). Krt76 was also strongly expressed in the palate (Figure 1b, f). Expression 
was observed in the buccal mucosa but not in the outer lip, defining a clear boundary between 
the two epithelia (Figure 1g). Krt76 expression was confined to the suprabasal layers in all oral 
epithelia (Figure 1c-g, i).  
 
Mouse stomach contains two well-defined areas: the non-glandular forestomach (also known as 
squamous stomach, which connects to the oesophagus) and the glandular stomach. Krt76 
expression was confined to the suprabasal layers of the squamous stomach (Figure 1h). 
Expression of Krt76 was further confirmed by antibody labelling (Figure 1c, i) and qRT-PCR 
(Figure 1j). 
 
Loss of Krt76 results in lymph node and spleen enlargement  
Although it was previously reported that loss of Krt76 results in hyperplasia of the buccal 
epithelium10, we observed no histological abnormalities in the tongue or forestomach and no 
obvious changes in epithelial proliferation in Krt76-/- mice, as assessed by EdU labelling (Figure 
2a-c). However, between the ages of 4 and 8 months all Krt76-/- mice spontaneously developed a 
large cyst (up to 17mm in diameter) between the lower jaw and the forelimbs (Figure 2d-f). Each 
cyst was filled with fluid and was juxtaposed to the salivary gland (Figure 2g). 
Immunofluorescence staining for B220 (CD45R) and CD3 revealed the presence of B and T 
cells, respectively, establishing that the cysts were enlarged submandibular lymph nodes (Figure 
2h, i). Flow cytometric analysis of the lymphocyte populations confirmed that the cyst cells were 
CD4+ or CD8+ mature T-cells (Figure 2j). Compared with the heterozygous controls (Krt76+/-), 
the lymph nodes in other body sites were also increased in size (Figure 2k), even though Krt76 
was not expressed in control lymph nodes (Supplementary Fig. 1a-b). Consistent with the 
increased size of the lymph nodes, there was a 2.2- to 3.9-fold increase in the absolute number of 
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mesenteric, submandibular, axillary and inguinal lymph node cells in Krt76-/- mice compared with 
heterozygous littermate controls (Figure 2l). 
 
No changes were observed in thymus size or cellularity (Figure 2m-o). However, Krt76-/- mice 
had enlarged spleens, with a 2.2-fold increase in the number of cells in the spleen (Figure 2p-r). 
In addition, adult Krt76-/- mice consistently weighed less than control mice (Figure 2s).  
 
We conclude that loss of Krt76 results in splenomegaly and lymphadenopathy, indicative of 
systemic inflammation. 
 
Increased effector and regulatory T cells  
To dissect the inflammatory phenotype of Krt76-/- mice, flow cytometric analysis of immune cell 
populations was performed. The percentage of total lymphocytes that were B cells (B220+ TCRβ-
) was increased in Krt76-/- mouse lymph nodes (Supplementary Fig. 1c-d) compared to 
heterozygous controls. The percentage of T cells (TCRβ+ CD3+ CD4+) that were effector T cells 
(CD4+ CD44high CD62Llow) was significantly increased in the spleen and lymph nodes (Figure 3a). 
Effector T cells are known to play an important role in anti-tumour immunity18. There was also a 
significant increase in regulatory T cells (Tregs; TCRβ+CD4+CD3+Foxp3+ 19) in the lymph nodes 
and thymus of Krt76-/- mice, but not in the spleen (Figure 3b). Tregs are potent anti-
inflammatory cells that, among other functions, impede the anti-tumour immune response in a 
variety of cancers20.  
 
The changes in the levels of T effector cells, Tregs and B cells correlated with a striking 
upregulation of circulating IL-6, IL-10, and TNFα (Figure 3c). The fluid inside the lymphoid 
cysts of Krt76-/- mice also had significantly elevated IL-6, IL-10 and TNFα (Figure 3d). The 
levels of IFNγ, IL-2 and IL-4 were not altered (Figure 3c). TNFα is known to stimulate Treg 
expansion21. 
 
To examine whether loss of Krt76 also resulted in local inflammation, we measured cytokine 
mRNA levels in the tongue and squamous stomach. This revealed a significant upregulation of 
TNFα in the tongue and IL-4 and TSLP in the squamous stomach (Figure 3e). Consistent with 
these local increase in cytokine production, the total immune cell infiltrate (total CD45+ cells) 
was significantly increased in the tongue and squamous stomach when compared to 
heterozygous controls (Figure 3f, g). We also confirmed the previously reported increase in the 
skin inflammatory infiltrate12,13 (Figure 3f, g). 
Taken together, these data demonstrate that loss of Krt76 results in local and systemic 
inflammation.  
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Characterisation of Tregs and T effector cells  
To discover whether the functionality of Tregs and T effector cells differed in Krt76-/- and 
control mice we performed in vitro suppression assays (Figure 4; Supplementary Fig. 2). Tregs 
were isolated from the spleen of control and Krt76-/- mice and co-cultured at different ratios 
with CFSE-labelled CD4+CD25- responder T cells, which include the T effector population 
(Tresp). The suppression of proliferation was measured by flow cytometry (Figure 4a, b). Krt76-/- 
Tregs inhibited Tresp proliferation more effectively than control Tregs, whether the Tresp were 
from control (Figure 4b) or Krt76-/- mice (Supplementary Fig. 2a). In addition, the proliferative 
activity of Krt76-/- Tresp in the absence of Tregs was lower than that of control Tresp (Figure 
4c).  
 
The higher suppressive capacity of Krt76-/- Tregs correlated with increased capacity to inhibit 
expression of the pro-inflammatory cytokines IFNγ and IL17 and the anti-inflammatory cytokine 
IL-10, whether the Tresp cells were from control (Figure 4d) or Krt76-/- mice (Supplementary 
Fig. 2b). Tregs from Krt76-/- mice expressed higher levels of the Treg suppressive markers CD39 
and CD73 compared to control Tregs (Figure 4e, f). CD39+ Tregs are known to suppress T cell 
proliferation and inflammatory cytokine production more efficiently than CD39 Tregs 22. The 
differences between the properties of Tregs from Krt76-/- and control mice did not reflect a 
difference in Foxp3 expression levels (Figure 4g).  
 
We conclude that Tregs from Krt76-/- mice have enhanced suppressive function and Tresp are 
less proliferative compared with cells from control mice. 
 
Increased tumour incidence in Krt76-/- mice 
To determine whether the loss of Krt76 directly impacts tumour incidence in the oral cavity, we 
treated control (wild-type Krt76+/+ and heterozygous Krt76+/-) and Krt76-/- mice with a synthetic 
carcinogen 4NQO 14 (Figure 5a) that mimics the carcinogenic effects of tobacco and alcohol 
ingestion15. In wild-type mice 4NQO induces carcinoma in the oral cavity and oesophagus, but 
not in the remainder of the digestive tract 23. Mice received 100µg/ml of 4NQO in the drinking 
water for 16 weeks and were monitored for the appearance and progression of lesions for a total 
of 28 weeks (Figure 5a). Hyperplasia of the dorsal tongue was evident by 6 weeks and from 10 
weeks mice had raised localised white lesions corresponding to dysplasias (Figure 5a-c). From 16 
weeks full oral squamous cell carcinomas (OSCC) began to appear in all regions of the oral cavity 
(Figure 5b-c) and by 22 weeks all mice had developed at least one tumour (Figure 5f). The 
development of tumours was similar in male and female mice. 
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To explore the significance of the downregulation of Krt76 that occurs in human oral squamous 
cell carcinomas (OSCC) 10, we monitored changes in the expression of Krt76 by LacZ labelling in 
4NQO-treated Krt76+/- mice. Krt76 downregulation was first observed in hyperplastic oral 
epithelium (Figure 5d; 13 out of 15 mice), consistent with the findings in human patients10. 10 
out of 13 dysplasias and 4 out of 4 invasive SCC had focal or total loss of Krt76 (Figure 5d, 
arrowed). Nevertheless, even when tumours developed within the same mouse, some lesions had 
lost Krt76 expression whereas others retained it (Figure 5d, I and II). This was confirmed with 
immunostaining for Krt76; as expected (Figure 1, Supplementary Fig. 3d), Krt76, when present, 
was co-expressed with differentiation markers such as Loricrin (Figure 5e). 
 
We next compared the incidence of oral cavity tumours in Krt76+/+, Krt76+/- and Krt76-/- mice 
(Figure 5f). There was no significant difference between Krt76+/+ and Krt76+/- mice; however, 
Krt76 -/- mice developed OSCC earlier. In Krt76-/- mice, the average onset of lesions was at 12 
weeks after treatment (n=16), compared to 17 weeks in control mice (n=14 Krt76+/+ and n=27 
Krt76+/-, p<0.0001). Furthermore, in Krt76-/- mice the incidence was 100% by 14 weeks (Figure 
5f, n=16). Many of the tumours had areas that were LacZ-negative, indicating downregulation of 
Krt76 or loss of Krt76-expressing cells (Figure 5d).  
 
None of the Krt76+/+ or Krt76+/- control mice developed tumours in the stomach by 28 weeks 
from the start of 4NQO treatment (Figure 5g). However, Krt76-/- mice started developing 
tumours in the squamous stomach by week 16 and by week 28 89% of the mice had a stomach 
tumour (Figure 5g). No tumours or dysplasias were observed in the glandular stomach, regardless 
of genotype (Figure 5h). As shown in Figure 5h (arrow), there was extensive downregulation of 
Krt76 expression in stomach tumours. 
 
We conclude that Krt76 ablation accelerates 4NQO-induced tumour progression in the tissues 
where Krt76 is expressed, namely the oral cavity and squamous stomach.  
 
Tongue and stomach epithelial integrity 
It has previously been reported that Krt76-/- epidermis exhibits reduced expression of tight 
junction proteins, Claudins, and an increase in the number of suprabasal layers12,13 
(Supplementary Fig. 3f). In contrast there was no reduction in Claudin1, Claudin3 or Claudin7 
expression in Krt76-/- tongue or stomach epithelium (Supplementary Fig. 3f). There was no 
difference in the total thickness of tongue and stomach epithelium between control and Krt76-/- 
mice, nor in the suprabasal (Loricrin, Filaggrin or Involucrin-positive) layers (Supplementary Fig. 
3d, e), although by Q-PCR a reduction in Involucrin was observed in Krt76-/- stomach 
(Supplementary Fig. 3f). 
	 8	
 
The epithelial integrity of the oral epithelia of Krt76-/- mice was assessed by a whole-mount 
Toluidine Blue dye penetration assay24 and was found not to be defective (Supplementary Fig. 
3b). Furthermore, following introduction of FITC-dextran by oral gavage there were no 
differences in the concentration of FITC-dextran in blood serum between control and Krt76-/- 
mice (Supplementary Fig. 3c). The previously reported delay in epidermal barrier formation12 was 
confirmed (Supplementary Fig. 3a). 
 
To examine whether there was increased penetration of commensal microorganisms that could 
lead to an activation of immune cells, we measured the bacterial load of the tongue and stomach 
epithelia by Gram staining and performed whole-mount fluorescence in situ hybridization 
(FISH) with a universal bacterial probe (BacUni) 25. Bacterial penetration was largely confined to 
the cornified layers of the tongue filiform papillae in both Krt76-/- and control mice, 
demonstrating that there was no significant difference in bacterial load or penetration 
(Supplementary Fig. 3g-h).  
 
We conclude that loss of Krt76 did not compromise the integrity and barrier properties of 
tongue and stomach epithelia and that the increased tumour incidence in Krt76-/- mice is not 
linked to defective epithelial barrier formation. 
 
Local and systemic inflammatory response to carcinogen 
Since Krt76-/- mice exhibit local and systemic inflammation, we examined whether this was 
exacerbated by 4NQO treatment. Tongue and squamous stomach were collected after 2 weeks of 
4NQO treatment to assess whether the levels of inflammatory cytokines were altered. The levels 
of cytokines were increased upon 4NQO treatment of both Krt76+/- control and Krt76-/- mice 
compared to untreated mice (Figure 6a compared to Figure 3c). However, blood serum levels of 
IFNγ, IL-4, IL-6, IL-10 and TNFα were significantly higher in 4NQO treated Krt76-/- than 
control mice (Figure 6a). 
 
In the tongue there were significantly more stromal CD45+ cells in Krt76-/- versus control mice 
prior to 4NQO treatment (Figure 3f, g), following 2 weeks of treatment and in 4NQO-induced 
hyperplasias (Figure 6b, arrowheads, 6c). In Krt76-/- stomach, the number of local CD45+ cells 
increased in the stroma adjacent to 4NQO-induced tumours (Figure 6d). 
 
Immunofluorescence labelling for Foxp3 revealed an increase of Tregs in both tongue and 
squamous stomach of Krt76-/- mice compared to control mice, whether normal or tumour-
bearing tissue (Figure 6e-h). The number of Tregs increased in hyperplasias and dysplasias of 
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Krt76-/- tongue compared to controls and there was a marked accumulation of Tregs in tumour 
stroma (Figure 6e, g, arrowheads, h). Furthermore, lesions in Krt76-/- tongue and stomach 
presented a concomitant decrease in effector T cells (Figure 6i). Total CD4+ cells were increased 
in the stomach but not in the tongue (Figure 6i). Consistent with the findings in mice, there was 
an increase in stromal FoxP3+ cells underlying Krt76-negative- regions of human OSCC (Figure 
7a) even when the differentiation marker Involucrin was still expressed (Figure 7b).  
 
Two cytokines that control Tregs are IL-18, which regulates Treg function26,27, and IL-33, which 
is constitutively expressed in barrier epithelial cells28,29 and promotes Treg accumulation and 
maintenance in inflamed tissues30. Consistent with the accumulation of Tregs, IL-18 levels were 
significantly increased in 4NQO treated (2 weeks) Krt76-/- compared to Krt76+/- tongue (Figure 
6j). In addition, IL-33 was increased in Krt76-/- tongue and squamous stomach after 4NQO 
treatment (Figure 6j).  
 
We conclude that the increased cancer susceptibility of Krt76-/- mice is correlated with an 
exacerbated systemic and inflammatory response to carcinogen, including the accumulation of 
Tregs in the tongue and squamous stomach. 
 
Increased Tregs correlate with accelerated tumour formation  
To examine whether targeting Tregs influences tumour onset in Krt76-/- mice, we developed 
mixed bone marrow (BM) chimeras by sublethally irradiating control and Krt76-/- mice and 
reconstituting them with BM from Depletion of Regulatory T Cell (DEREG) transgenic mice31 
(Figure 8a, b). DEREG mice express a diphtheria toxin receptor-enhanced green fluorescent 
protein (DTR-eGFP) fusion protein under control of the endogenous Foxp3 promoter, allowing 
both visualisation and diphtheria toxin-induced ablation of Foxp3+ Tregs. Successful engraftment 
was verified by analysing the percentage of Foxp3GFP+ Tregs in the chimeras 6 weeks after 
reconstitution (Figure 8c). As expected, there were more Foxp3GFP+Tregs in Krt76-/- than 
control mice (Figure 8c).  
 
We ablated donor Tregs by injecting diphtheria toxin (DT, or PBS as a control) for the first 5 
weeks of the 4NQO carcinogenesis protocol (Figure 8b). This time point was selected to 
coincide with the development of hyperplasia (Figure 6h). After DT-injection for 5 weeks, donor 
Foxp3GFP+ Tregs were significantly reduced in DEREG/Krt76-/- and control 
DEREG/Krt76+/+ chimeric mice (Figure 8c). However, when all the mice in each cohort had 
developed tumours and were subjected to end-point analysis, the total number of Tregs was 
significantly increased in DT-treated compared to PBS-treated DEREG/Krt76-/- mice (Figure 
8d). In control DEREG/Krt76+/+ mice, the increase in lymph node Tregs following DT 
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treatment was not statistically significant (Figure 8d). However, in the spleen of DT-treated 
DEREG/Krt76+/+ mice there was a significant increase in Tregs (Figure 8e). Further analysis of 
Krt76-/- chimeras (Figure 8f) showed that while, as expected, donor GFP+ Tregs were reduced 
there was a significant increase in recipient GFP- Tregs, accounting for the increase in total 
Tregs.  
 
Quantitation of 4NQO-induced carcinogenesis revealed that DT treatment accelerated tumour 
formation in both control and Krt76-/- mice (Figure 8g). Thus higher levels of Foxp3+ Tregs 
correlate with more rapid tumour development in both control and Krt76-/- mice. The major 
effect of Krt76 deletion on tumour susceptibility may therefore be via enhanced accumulation of 
Tregs.  
 
 
DISCUSSION 
Stratified, terminally differentiated epithelia, such as epidermis and oral epithelium, provide 
protective barriers against the environment, and their function depends on structural proteins, 
such as keratins. Until recently, keratins were mainly regarded as cytoskeletal scaffolds; however, 
there is an emerging role for keratins in the regulation of epidermal immunity 3-6,8,32,33. For 
example, Krt1 is not only crucial to maintain skin integrity, but also regulates innate immunity by 
restricting IL-18 release from keratinocytes 5. Krt17 acts as a regulator of skin immune responses 
and loss of Krt17 promotes reduced cell proliferation, leading to a delay in skin tumour onset 6. 
Likewise, Krt16 regulates early inflammation and innate immunity in skin 32. 
 
Krt76 is the most significantly downregulated gene encoding a structural protein in human 
OSCC10,34 and downregulation correlates strongly with poor prognosis10. We have found that 
Krt76-null mice exhibit a marked inflammatory disease phenotype with systemic components: 
splenomegaly and lymphadenopathy (Figure 2). This is correlated with a significant expansion of 
B cells (Supplementary Fig. 1c, d), effector T cells and Tregs (Figure 3a, b), as well as an 
upregulation of inflammatory cytokines (Figure 3c).  
 
The Krt76-/- mouse serves as a model to explore the link between chronic inflammation and 
cancer, providing an opportunity to examine the impact of aberrant epithelial differentiation and 
consequent chronic inflammation on tumorigenesis. It is known that Krt76-/- mice do not 
develop spontaneous tumour lesions in the oral mucosa10 or skin. However, we have shown that 
in response to 4NQO treatment Krt76-/- mice are more predisposed to developing tumours in 
those sites where Krt76 is normally expressed, namely the tongue and squamous stomach (Figure 
5f, g).  
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The enhanced sensitivity of Krt76-/- mice to carcinogenesis was not due to defective epithelial 
barrier formation. In addition, although some of the effects of Krt17 are attributable to its 
nuclear location6,33, we failed to detect nuclear Krt76 by antibody labelling and Krt76 is not 
predicted to have a nuclear localisation signal35. Instead the cancer susceptibility of Krt76-/- mice 
correlated with a higher number of Tregs in secondary lymphoid organs and an enhanced 
accumulation of Tregs in the tongue and squamous stomach, which increased further in the 
tumour microenvironment (Figure 6e-h). There was also a reduction in effector T cells in Krt76-
/- mice in the tumour microenvironment. We conclude that keratins not only regulate 
inflammation and immunity in the skin (reviewed in 3) but also in the oral cavity and squamous 
stomach.  
 
Tregs were originally identified because of their ability to prevent organ-specific autoimmune 
disease by maintaining lymphocyte homeostasis and regulating activated T cells20. However, there 
is emerging evidence that they play a major role in the tumour microenvironment20,36 and 
contribute to tumour growth and progression by inhibiting the antitumor immune response19,26,37. 
Increased numbers of FoxP3+/CD25+ Tregs are observed in a subset of human OSCC and in 
the early stages of tumour progression in several mouse models 38. While this has been linked to 
an immunosuppressive tumour microenvironment 39-42, there is still controversy about whether 
tumours with increased Tregs have a better or worse prognosis 43.  
 
Krt76-/- mice exhibited deregulated cytokine expression. Anti-tumour function of dendritic cells 
is suppressed through IL-10 44 and we found IL-10 to be upregulated in Krt76-/- mice, 
particularly after 4NQO treatment. Increased levels of IL-10 are also reported in patients with 
OSCC 45. However, IL-6, which is a key cytokine in encouraging cancer cell proliferation 46, was 
also upregulated in Krt76-/- mice. After carcinogen treatment, we observed an increase in serum 
IFNγ (Figure 6a), consistent with the fact that IL-18, which is also upregulated (Figure 6j), 
stimulates IFNγ production47. Krt76-/- effector T cells produced more IFNγ than control 
effector T cells in culture (cf. Figure 4d and Supplementary Fig. 2b). 
 
In addition to being more abundant, Tregs from Krt76-/- mice had enhanced suppressive 
function, which correlated with higher levels of CD39 and CD73 expression (Figure 4). CD39 is 
expressed on human and murine Tregs and is known to mediate immune T cell suppression by 
the downstream production of adenosine48. CD39+ Tregs suppress T cell proliferation more 
efficiently than CD39- Tregs22. The coordinated expression of CD39 and CD73 on Tregs in 
Krt76-/- mice can explain their enhanced suppressive function. Tregs from CD39-/- mice have 
impaired suppressive function in vitro and fail to block transplant rejection in vivo 48. Furthermore, 
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Treg expression of CD39 and CD73 is greater in human HNSCC than in healthy tissue49, 
characterised by increased adenosine-mediated suppression of effector T cells 48,49. 
 
In support of a positive role for Treg in 4NQO carcinogenesis, we found that partial depletion of 
donor Tregs in chimeric mice led to an increase in total Tregs and a corresponding acceleration 
of tumour formation, both in Krt76-/- and control mice. We propose that upon loss of Krt76 the 
increase in the immunosuppressive Treg infiltrate leads to a failure in anti-tumour immunity 
linked to exaggerated suppression of anti-tumour-associated antigen-reactive lymphocytes. How 
loss of Krt76 exerts its effects requires further investigation; however, mechanisms involving 
inflammasome activation50 or epithelial production of danger-associated molecular pattern 
(DAMP) proteins51 are possibilities. 
 
The inability to resolve chronic inflammation is considered one of the initial triggers of 
carcinogenesis52, while immunosuppression is a crucial tumour immune-evasion mechanism and 
the main obstacle to successful tumour immunotherapy20. Our study highlights the importance of 
keratins as immunomodulators and the potential significance of highly suppressive CD39+ Tregs 
in OSCC, making them potentially attractive targets for new cancer therapies. The Krt76-/- 
mouse provides a paradigm for understanding how the differentiated epithelial layers contribute 
to oral carcinogenesis by provoking both local and systemic immune responses 43. 
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METHODS  
 
Animal procedures 
All animal procedures were subject to institutional ethical review and performed under the terms 
of a UK Home Office license. KRT76-/- (Krt76tm1a(KOMP)Wtsi) mice were obtained from the 
Wellcome Trust Sanger Institute Mouse Genetics Project 13,16,17. Heterozygous Krt76+/- mice 
were crossed to obtain knockout (Krt76-/-) and littermate control (heterozygous Krt76+/- or wild 
type Krt76+/+) mice. DEREG mice31 were kindly provided by Caetano Reis e Sousa (The Francis 
Crick Institute). Mice were maintained on the C57Bl/6N genetic background.  
 
In some experiments, mice received a dose of 500µg EdU (5-ethynyl-2'-deoxyuridine, Invitrogen) 
in PBS intraperitoneally 2h before tissues were harvested to assess proliferation. Tregs were 
depleted by intraperitoneal injection of 20ng diphtheria toxin (DTX; Sigma) per g mouse (as in 
Figure 8b), once a week for 5 weeks53. Grafting efficiency was confirmed by analysing Foxp3 
GFP+ cells by flow cytometry at indicated time-points. Sample sizes were determined on the 
basis of prior power calculations. 
 
Human samples 
Human tissues were obtained from the Guy’s & St Thomas’ NHS Foundation Trust research 
biobanks, which are licensed by the Human Tissue Authority (licence number 12121).  
 
Bone marrow reconstitution 
In BM transplantation experiments (Figure 8), 8- to 16-week-old male and female Krt76-/- and 
control littermate recipients (Krt76+/-) were treated with acidified water at least 10 days before 
irradiation. Statistical power was calculated using the resource equation and animals were 
randomly assigned to treatment groups. Allogenic BM transplants were performed 24h after total 
body irradiation (two times 5.5 Gy, separated by 3 h). Donor BM was isolated from the tibia and 
femur of male mice. BM reconstitution was performed by intravenous injection of 2x106 BM 
cells in 200µl PBS. Chimerism was confirmed by analysing Foxp3GFP+ cells in the blood by flow 
cytometry. 
 
4NQO carcinogenesis  
4NQO (Sigma, diluted to 100 µg/ml) was administered in the drinking water and fed to mice as 
the sole source of drinking water during the carcinogen-treatment period. 4NQO-containing 
water was prepared and changed once a week for 16 weeks. After that period, mice were given 
normal drinking water. During the experiments, the mice were maintained with regular mouse 
chow and water (with or without 4NQO) ad libitum. Once a week 4NQO-treated mice were 
sedated with inhaled isoflurane and the oral cavities were screened for lesions (hyperplasias, 
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dysplasias and SCCs). 
 
Flow cytometry 
Lymph nodes, thymus and spleen were harvested from treated mice, mechanically disrupted, 
passed through a 40µm cell strainer (BD Falcon) and rinsed with PBS to remove debris. Red 
blood cells were lysed using Ammonium-Chloride-Potassium Lysing Buffer. Cell number was 
determined using a Scepter Cell Counter (Merck Millipore).  Tongue and stomach tumours were 
dissociated using Tumour Dissociation Kit (Miltenyi Biotec) according to the manufacturer’s 
recommendations. 
 
Single cells were labelled according to standard procedures. Briefly, single-cell suspensions were 
washed once in Stain Buffer and resuspended at 1x106 cells/ml. Nonspecific staining was 
blocked with Fc block (CD16/CD32, clone 93) prior to cell surface staining with the following 
antibodies: CD3ε PECy7 (145-2C11), CD3ε FITC (145-2C11), CD4 PerP.Cy5.5 (RM4-5), CD4 
PE (RM4-5), CD8α PE (53-6.7), CD8α FITC (53-6.7), CD8 BV605 (53-6.7), TCRβ APC (H57-
597), B220 APCCy7 (RA3-6B2), CD25 APCe780 (PC61.5), CD62L PerCPCy5.5 (MEL-14), 
CD73 FITC (eBioTY/11.8), CD39 PE (24DM51), CD44 AlexaFluor700 (IM7) (all from 
eBioscience, used at 1/100 dilution). 
 
Intracellular staining for Foxp3 PE-Cy7 (FJK.165, eBioscience) was performed after fixation with 
Foxp3 Fixation Buffer and permeabilization with Foxp3 Permeabilization Buffer (eBioscience). 
4’,6-Diamidino-2-phenylindole (DAPI, Molecular Probes) was used to exclude dead cells, or 
Fixable viability Dye eFluor 455UV (eBioscience) in intracellular staining. Labelled cells were 
analysed on a BD LSRFortessa cell analyser. All data were analysed using FlowJo software. The 
gating strategy for Treg and effector T cell populations is shown in Supplementary Fig. 4.  
 
Histology  
For frozen sections, tissues were embedded in OCT (optimal cutting temperature compound), 
sectioned and post-fixed in 4% paraformaldehyde/PBS pH 7.4 for 10 min before staining. X-gal 
staining on frozen sections was performed as described54. The tissues were sectioned and stained 
with haematoxylin and eosin (H&E) and with Gram stain (Sigma) by conventional methods. 
Images were acquired using a Hamamatsu slide scanner and analysed using NanoZoomer 
software (Hamamatsu). 
 
Immunofluorescence staining 
Frozen sections were fixed in 2% paraformaldehyde/PBS pH 7.4 and blocked with 10% goat 
serum, 2% BSA, 0.02% fish skin gelatin and 0.05% TritonX100 (Sigma) in PBS for 1h at room 
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temperature. Paraffin sections of human OSCC were subjected to heat-mediated antigen retrieval 
(citrate buffer, pH6) prior to blocking. Primary antibodies were incubated overnight at 4°C, 
followed by 1h incubation at room temperature in secondary antibody.  
 
The following primary antibodies were used: Foxp3 (eBioscience, clone FJK-16s, 1/100, and 
Abcam, clone 236A/E7, 1/50), anti-Loricrin, anti-Krt76 (Santa Cruz, clone F-12, 1/100, and 
Sigma, HPA019656, 1/100), Krt14 (Covance, PRB-155P, 1/1000), B220/CD45R (eBioscience, 
clone RA3-6B2, 1/100), CD3 (BD Pharmingen, clone 17A2, 1/150), CD45 (BD Pharmingen 
clone 30-F11, 1/150); and secondary antibodies: anti-goat, anti-mouse and anti-rabbit Alexa 
Fluor 488, 568 and 633 (Life Technologies, 1/300).  
 
EdU staining was performed with a Click-it EdU imaging kit (Life Technologies) according to 
the manufacturer’s recommendations. DAPI (Life Technologies) was used as a nuclear 
counterstain. Slides were mounted using ProLong Gold anti-fade reagent (Life Technologies). 
Images were acquired with a Nikon A1 Upright Confocal microscope. Images were analysed 
using ICY software. 
 
Quantification of cell number and epithelial thickness 
Images were quantified using open-source ICY software plug-in Manual Counting55. Positively 
stained cells for CD45, EdU or Foxp3 were counted per length of the epithelium analysed or per 
stromal area (as delineated in Figure 3). The total number of nuclei was quantified using DAPI 
staining. All cell count analyses were performed using sequential sections from well-oriented 
tongue or stomach blocks in a blind manner on an average of 10 independent fields per animal 
(n=3-6 animals/genotype/experiment). Representative images from two to three independent 
experiments with at least three biological replicates per group are shown. All statistical analyses 
were carried out using Prism 7 (Graph Pad). 
 
Fluorescence in-situ hybridisation with BacUni 
Pieces of tongue and stomach epithelia were collected and sectioned in a sterilized setup. 
Sections were fixed in 1:1 acetone-to-methanol and incubated with PNA FISH probes at 55°C. A 
universal bacteria probe (BacUni; AdvanDx) and probe for C. dubuliniensis (AdvanDx) were 
used25. DAPI was used for nuclear counterstaining. Slides were mounted using ProLong Gold 
anti-fade reagent (Life Technologies). Images and Z-stacks were acquired with a Nikon A1 
Upright Confocal microscope. Evaluation of bacterial location was performed on three-
dimensional z-stacks using ICY software.  
 
Epithelial permeability assays 
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Whole embryos or dissected tongues were dehydrated through a methanol series (25%, 50%, 
75%, and 100% methanol, 60 s per step), rehydrated in PBS, and then stained immediately with 
0.1% toluidine blue in water for 10 min, with agitation at room temperature. Samples were briefly 
washed in PBS and immediately photographed using a Nikon SWZ18 and Nikon DS-Ri2 camera. 
 
Stomach barrier function was assessed using a FITC-labelled dextran method. Briefly, food and 
water were withdrawn for 4h and mice were sedated with inhaled isoflurane and orally 
administrated with the permeability tracer by oral gavage (60 mg/100 g body weight of FITC-
labelled dextran, MW 4000; FD4, Sigma-Aldrich). After 30min, blood was collected by cardiac 
puncture into Microtainer SST tubes and fluorescence intensity was determined using GloMax® 
Discover Multimode Microplate Reader (Promega; excitation, 492 nm; emission, 525 nm). FITC-
dextran concentrations were determined using a standard curve generated by serial dilution of 
FITC-dextran. 
 
Tissue collection, RNA extraction and gene-expression analysis 
Biopsies were homogenized using GENTLEMACS (Miltenyi Biotec) according to the 
manufacturer’s recommendations. Total RNA from homogenised tissues was isolated and 
purified using the Purelink RNA micro kit (Invitrogen) with on-column DNaseI digestion, 
according to the manufacturer’s instructions. Complementary DNA was generated using 
SuperScriptIII (Invitrogen). Quantitative real-time PCR reactions were performed with TaqMan 
Fast Universal PCR Master Mix and Taqman probes (Thermo Fisher Scientific, Supplementary 
Table 1) on a 7900HT real-time PCR machine (Applied Biosystems) on biological triplicates  
 
In vitro T-cell suppression assay 
CD4+ T lymphocytes were purified from splenic cell suspensions using Dynabeads® 
Untouched™MouseCD4 Cells kits (Life Technologies) followed by CD25+ magnetic-activated 
cell sorting (MACS) according to the manufacturer’s instructions (Miltenyi Biotec). Cell purity 
was >96% as determined by flow cytometry. 1x106 cells/ml were resupended in complete RPMI-
1640 medium (Thermo Fisher Scientific) containing L-glutamine (2 mM, Gibco), 
penicillin/streptomycin (100 U/ml, Gibco), HEPES (1mM, Gibco), 2-Mercapthoethanol (50mM, 
Gibco) and 10% fetal calf serum (Thermo Fisher Scientific). CD4+ CD25- T effector cells (Tresp) 
were labelled with 5nM CFSE (Vybrant CFDA SE Cell Tracer kit, Molecular Probes, Life 
Technologies) for 15min at 37°C, resuspended at a concentration of 1x106 cells/ml in complete 
RPMI-1640 medium and co-cultured with different numbers of CD4+ CD25+ Tregs at a range of 
dilution ratios, in the presence of 10x105 antigen-presenting cells and monoclonal anti-CD3e 
mAb (1µg/ml, clone 145-2c11, BD Pharmingen), in a final volume of 200µl culture medium in 
96-well round-bottom plates. Each sample was tested in duplicate or triplicate. After culture for 
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72 hours at 37°C in a humidified atmosphere of 5% CO2, Near-IR Live/Dead fixable dead cell 
stain kit (ThermoFisher) was added to exclude dead cells and CFSE dilution was analysed by 
flow cytometry using a BD LSRFortessa. All data were analysed using FlowJo software. Relative 
proliferation was calculated as proliferation index without or with Tregs and % suppression 
calculated.  
 
Cytokine analysis by cytometric bead array multiplex assays 
Blood was collected by cardiac puncture and left to clot for 2h. Serum was collected after 
centrifugation for 20 min at 4°C. Supernatants from the suppressions assays were collected and 
kept at -80ºC prior to analysis. Levels of IFNγ, IL-2, IL-4, IL-6, IL-10 and TNFα were analysed 
in the serum or in cell culture supernatants using a mouse cytometric bead array Th1/Th2/ Th17 
cytokine kit (BD Biosciences) following the manufacturer’s instructions. Data were acquired 
using the BD FACSCanto system (BD Biosciences) and analysed using FlowJo software. All 
samples were measured in technical duplicates and biological replicates (n=4 for each group). 
 
Statistical analysis 
All graphs and statistical calculations were generated using Prism7 (GraphPad) software. 
Statistical significance was computed with the test indicated in each figure legend. The number of 
experiments and animals analysed are indicated in each figure. 
 
Data Availability 
The data that support the findings of this study are available from the authors on request. 
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FIGURE LEGENDS 
 
Figure 1 – Keratin 76 is expressed in the oral epithelia and squamous stomach.  
(a) Krt76 knockout strategy. Krt76-/- mice were generated by disruption of the Krt76 gene via a 
knockout first allele targeting construct (reporter-tagged insertion with conditional potential). 
These animals have a splice acceptor-LacZ reporter gene integrated in the targeting gene, 
between exon 1 and 2, which allows tracing of gene expression whilst disrupting Krt76 protein 
expression. (b) X-gal staining (blue) of beta-galactosidase expressed under the control of the 
Krt76 promoter in the oral cavity and stomach (arrows) of Krt76+/- mouse embryos at E17.5. (c) 
	 21	
Immunofluorescence labelling with anti-Krt76 (green) and anti-Krt14 (red) antibodies in the oral 
cavity and stomach of mouse embryos at E17.5. Bottom row: left hand panel is higher 
magnification view of boxed area in right hand panel. (d) Whole mount X-gal staining of 
Krt76+/- reporter mice at post-natal day 2 (P2) shows Krt76 expression in the dorsal and lateral 
tongue, with partial expression in the ventral tongue. (e, f, g, h) X-gal staining (blue) of beta-
galactosidase expressed under the control of the Krt76 promoter in tongue (e), palate (f), lip and 
buccal mucosa (g) and in stomach (h) of Krt76+/- adult mice. (h) Mouse stomach is subdivided 
into two major histologically distinct regions: the squamous stomach lined with a stratified 
squamous epithelium and the glandular stomach, separated by the limiting ridge from the 
stratified squamous epithelium of the squamous stomach. Krt76 expression is restricted to the 
squamous stomach region. (i) Immunofluorescence labelling with anti-Krt76 (green) and anti-
Krt14 (red) antibodies of adult wild type mouse tissues, confirming the specificity of both anti-
Krt76 antibody and X-gal staining. Samples were counterstained with nuclear dye DAPI (4’,6-
diamidino-2-phenylindole). Doted line delineates basement membrane. (j) Krt76 mRNA qRT-
PCR analysis of adult tissues, relative to Gapdh (n=3 mice, means ± s.e.m. are shown). Scale 
Bars = 500µm (b, c), 100µm (e-i). 
Figure 2 – Loss of Krt76 leads to enlarged lymph nodes and spleen, without affecting 
tongue and stomach epithelial homeostasis. 
Immunostaining (a) and quantification (b) of EdU-labelled cells per mm of tongue and 
squamous stomach epithelia (n=3 mice/genotype, 2 sections/mouse and >6 fields quantified per 
section, means ± s.e.m. are shown).  (c) Hematoxylin-eosin (H&E) stained sections. (d) Krt76-/- 
6 month-old mouse with a neck cyst (arrowed). (e) Mean age (± s.e.m.) of onset of macroscopic 
neck lymphoid cysts in Krt76-/- (n=16) and control mice (n=41) (****p≤0.0001, unpaired t-test). 
(f) Macroscopic views of submandibular lymph nodes from control and Krt76-/- mice and cyst 
from Krt76-/- mouse. Pictures are representative of 9 mice/genotype. (g) Hematoxylin-eosin 
stained sections of neck lymphoid cyst inside the lymph nodes (LN) at early (left) and advanced 
(right) stages, juxtaposed to the salivary glands (SG). (h, i) Immunofluorescence staining of 
lymph nodes and lymphoid cyst sections  with (h) anti-B220 (B cell marker) and (i) anti-CD3 (T 
cell marker) with DAPI counterstain. (j) Representative flow cytometry dot plots showing T cell 
populations from thymus (CD4+ and CD8+), submandibular lymph nodes (CD4+ or CD8+) and 
neck lymphoid cyst (CD4+ or CD8+, as the lymph nodes) from Krt76-/- and control mice, 
showing percentages of total live cells (n=3 experiments, n=4 mice/experiment/genotype). (k) 
Lymph nodes from control and Krt76-/- mice. Pictures are representative of 9 mice from each 
genotype. (l) Quantification of the total absolute number of cells in lymph nodes of control and 
Krt76-/- mice. (m, n) Thymus size (m) and thymus cell number (n) in control and Krt76-/- mice. 
(o) Representative photograph of thymus from control and Krt76-/- mice. (p, q) Spleen weight 
(p) and absolute spleen cell numbers (q) in control and Krt76-/- mice. (r) Representative 
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photograph of spleens from control and Krt76-/- mice. (s) Total body weight of control (n=27) 
and Krt76-/- (n=10) mice. (l, m, n, p, q) mean ± s.e.m., *p≤0.05, **p≤0.01, ***p≤0.001, 
****p≤0.0001, unpaired t-test, n=4 mice/genotype, measured in duplicate and experiment 
repeated twice. Scale bars: 100µm (a, c, g, h, i), 500µm (f, k, o, r). Sub, submandibular; Ax, axillar; 
Mes, mesenteric; Ing, inguinal. 
Figure 3 – Loss of Krt76 results in local and circulating increase of cytokines and 
expansion of Tregs. 
(a, b) Summary of flow cytometric analysis of % effector T cells (CD44high CD62Llow) (a) and 
Foxp3+ Tregs (b) in total TCRβ+ CD3+ CD4+ T cells in thymus (Thy), spleen (Spl) and lymph 
nodes (LN; sLN, submandibular lymph nodes) from control and Krt76-/- mice (n=4 
mice/genotype, mean ± s.e.m., unpaired t-test). (c, d) Levels of cytokines in blood serum (c) 
and cyst fluid (d) of control and Krt76-/- mice assessed by CBA analysis (n=4 mice per genotype; 
experiment repeated twice, mean ± s.e.m., unpaired t-test). The same blood serum measurements 
for Krt76-/- mice are shown in (c) and (d). (e) Quantitative RT-PCR of cytokine mRNAs, 
relative to Gapdh, in tongue and squamous stomach epithelia (n=4 mice/genotype, mean ± 
s.e.m. of biological and technical triplicates; unpaired t-test). (f, g) Representative images of 
CD45 (green) and Keratin14 (red) stained sections of skin, tongue and squamous stomach 
epithelia (f), and quantification of infiltrating CD45+ leukocytes/mm2 of stromal region (g). 
Stromal region corresponds to area between the epithelium and the white doted line; n=3 mice 
per condition, 2 sections per mouse and >4 microscopic views per mice, means ± s.e.m., 
***p≤0.001, ****p≤0.0001, unpaired t-test). *p≤0.05; **p≤0.01; ***p≤0.001; ***p≤0.001; ns, 
non-significant. Scale bars: 100µm. 
Figure 4 - Phenotype and suppressive function of Krt76-/- Tregs. 
(a) Representative plots from a suppression assay involving different ratios of Tresp to Treg, 
showing CFSE profile quantified by flow cytometry after gating on CD4+ cells. This illustrates 
dose-dependent suppression of wild-type CD4+ CD25- Tresp proliferation in the presence of 
control or Krt76-/- Tregs. (b) Cumulative data showing % control Tresp suppression at each 
Tresp:Treg ratio in the presence of control or Krt76-/- Tregs. Mean ± s.e.m, 2 independent 
experiments, 2-way ANOVA, p<0.0001, Non-linear regression (curve fit) of Treg suppression. 
(c) Representative plots of Tresp CFSE profiles after gating on CD4+ cells, illustrating 
proliferation of Tresp from Krt76-/- and control mice in the absence of Tregs. (d) Levels of 
cytokines in cell culture medium for each Tresp:Treg ratio, assessed by CBA analysis (means ± 
s.e.m., multiple t-tests and two-way ANOVA, each culture condition in triplicate, measured in 
duplicate,  experiment repeated twice). (e) Summary of flow cytometric analysis of % CD39+ and 
CD73+ Tregs from total Tregs (CD4+ CD25+ Foxp3+) in spleen (Spl), lymph nodes (LN) and 
submandibular LN (sLN) from control and Krt76-/- mice. (f, g) Maximum intensity fluorescence 
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(MFI) of CD39, CD73 (f) and Foxp3 (g) expression in CD4+ CD25+ Foxp3+ Tregs (n=4 
mice/genotype, experiment repeated twice, mean ± s.e.m., unpaired t-test). *p≤0.05; **p≤0.01; 
***p≤0.001; ****p≤0.0001; ns, non-significant).   
 
Figure 5 – Tongue and squamous stomach tumour incidence in Krt76-/- mice. 
(a) Schematic of 4NQO tumorigenesis protocol. (b) Representative macroscopic views of each 
stage of tongue tumour development. (c, d) Representative images of hematoxylin & eosin 
staining (H&E) (c) and X-gal staining (blue) (d) and respective macroscopic views of the tongue 
of control (n=41 mice) and Krt76-/- mice (n=16 mice). X-gal staining is used to visualize Krt76 
expression. (e) Immunostaining for Krt76 (green) and Loricrin (red) (terminal differentiation 
marker) in a tongue section bearing two tumours, one of which expresses Krt76. (f) Tumour 
incidence in Krt76+/+ (n=14, median=17weeks), Krt76+/- (n=27, median=16weeks) and Krt76-/- 
mice (n=16 mice, median=10.5weeks) (no significant difference between the wild-type Krt76+/+ 
and the heterozygous Krt76+/- controls; ****p<0.0001 for Krt76-/- when compared to both 
controls; one-way ANOVA, Mantel-Cox test and Grehan-Breslow-Wilcoxon test). (g) Incidence 
of squamous stomach tumours in control (Krt76+/+ and Krt76+/-) (n=16) and Krt76-/- mice 
(n=9) harvested 16-28 weeks after the initiation of 4NQO treatment. (h) Representative images 
of H&E and X-gal staining (blue) of tumours in the squamous stomach. X-gal staining is used to 
visualize Krt76 expression. Dotted lines delineate the squamous stomach area. Scale bars: 100µm. 
Figure 6 – Infiltration of immune cell populations in tumour stroma. 
(a) Levels of cytokines in blood serum of control and Krt76-/- mice after 2 weeks of 4NQO 
treatment, assessed by CBA analysis (means ± s.e.m., unpaired t-test, 4 mice per genotype, 
measured in duplicate, experiment repeated twice). (b) Representative images of CD45 and 
Keratin 14 immunostaining in tongue lesions treated with 4NQO. Arrow and arrowhead indicate 
local accumulations of CD45+ cells. (c) Quantification of infiltrating CD45+ leukocytes in 
4NQO-treated tongue (n=3-8 mice/genotype, >4 microscopic views per region, means ± s.e.m., 
unpaired t-test). (d) Representative image of CD45 and Keratin 14 expression in stomach 
tumour. (e) Representative images of Foxp3+ Tregs in 4NQO-treated normal tongue (i.e. prior 
to development of hyperplasia) and dysplasias in control and Krt76-/- mice. (f, g) Representative 
images of immunostaining of Foxp3+ Tregs in 4NQO-treated normal stomach (f) and tumours 
(g). (e-g) Dashed lines denote epithelial-stromal boundary; arrowheads denote FoxP3+ cells. (h) 
Quantification of infiltrating Foxp3+ Tregs in 4NQO-treated tongue and squamous stomach 
(n=3-8 mice per condition and per genotype, >4 microscopic views per region, means ± s.e.m., 
unpaired t-test).  (i) Summary of flow cytometric analysis of % CD45+, CD4+ or effector T cells 
(CD4+ CD44+ CD62Llow) cells in total live cells, and Foxp3+ Tregs in total CD4+ CD25+ T cells, 
in tongue and stomach epithelia after 4NQO treatment of control and Krt76-/- mice (n=4 
mice/genotype, means ± s.e.m., unpaired t-test). (j) Quantitative RT-PCR of IL-18 and IL-33 
	 24	
mRNAs in 4NQO-treated tongue and squamous stomach, normalized to glyceraldehyde 3-
phosphate dehydrogenase (n=4 mice/genotype, means ± s.e.m. of biological and technical 
triplicates; unpaired t-test). *p≤0.05, **p≤0.01, ***p≤0.001; ****p≤0.0001; ns, non-significant. 
Scale bars: 100µm. 
Figure 7 – Krt76 expression and Foxp3+ Treg infiltration in human OSCC.  
(a) Representative images of H&E staining and immunostaining for Krt76 and Foxp3+ Tregs in 
human OSCCs. (b) Representative images of immunostaining of Krt76, keratin 14 (Krt14) and 
involucrin (IVL) with nuclear DAPI counterstain in human OSCC. Scale bars: 100µm. 
Figure 8 – 4NQO-induced carcinogenesis in DEREG chimeric mice.  
(a) Experimental scheme. Recipient mice were irradiated with 5.5Gy twice and received 2x106 
cells from DEREG mouse BM by tail vein injection. Mice were allowed to recover for 6 weeks 
before injecting DT to ablate Treg. Control mice were injected with PBS. (b) Schematic of BM 
transfer and Treg ablation by injecting PBS control or DT for 5 weeks, followed by the 4NQO 
tumorigenesis protocol. (c) Efficiency of engraftment by Foxp3GFP+ donor Tregs and 
percentage of donor Treg depletion after DT treatment confirmed by flow cytometric analysis of 
blood cells. (d, e) Summary of flow cytometric analysis of % total Tregs (CD4+ CD25+ Foxp3+) 
in total CD4+ cells in lymph nodes (d) and spleen (e) of control DEREG/Krt76+/- (d, e) and 
DEREG/Krt76-/- (d) chimeric mice treated with DT or PBS. (n=4-6 animals/group, mean ± 
s.e.m., Mann-Whitney test). (f) Summary of flow cytometric analysis of % donor (CD4+ CD25+ 
Foxp3+ GFP+) and recipient (CD4+ CD25+ Foxp3+ GFP-) Foxp3+ Tregs in total CD4+ lymph 
node cells from DEREG/Krt76-/- chimera mice treated with DT or PBS (n=4-6 animals/group, 
mean ± s.e.m., unpaired t-test). (g) Tumour incidence in DEREG/Krt76+/+ and 
DEREG/Krt76-/- chimeric mice treated with DT or PBS (n=5-6 animals/group, one-way 
ANOVA, Mantel-Cox test, p=0.013 for DEREG/Krt76-/- and p=0.016 DEREG/Krt76+/-). 
*p≤0.05, **p≤0.01, ***p≤0.001; ns, non-significant. 
 
 








